Caveat: I believe Nader when he says Dr. Lalezari
Post# of 148175
If that is the case, it suggests to me that the FDA may be catching on to the ARDS/RANTES hypothesis. If THAT is the case, the "Other criteria" should be all the backup data needed (and more) to corroborate any clinical outcomes from the studies. Hope someone can confirm with Dr. L on the next webcast.